Last reviewed · How we verify

DNL343 — Competitive Intelligence Brief

DNL343 (DNL343) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LRRK2 kinase inhibitor. Area: Neurology.

phase 2 LRRK2 kinase inhibitor LRRK2 (leucine-rich repeat kinase 2) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

DNL343 (DNL343) — Denali Therapeutics Inc.. DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DNL343 TARGET DNL343 Denali Therapeutics Inc. phase 2 LRRK2 kinase inhibitor LRRK2 (leucine-rich repeat kinase 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LRRK2 kinase inhibitor class)

  1. Biogen · 1 drug in this class
  2. Denali Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DNL343 — Competitive Intelligence Brief. https://druglandscape.com/ci/dnl343. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: